Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine - 500 Beiträge pro Seite
eröffnet am 01.06.09 10:55:35 von
neuester Beitrag 18.07.10 12:35:44 von
neuester Beitrag 18.07.10 12:35:44 von
Beiträge: 49
ID: 1.150.754
ID: 1.150.754
Aufrufe heute: 1
Gesamt: 2.045
Gesamt: 2.045
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 51 Minuten | 2067 | |
| vor 37 Minuten | 1996 | |
| vor 1 Stunde | 1299 | |
| vor 49 Minuten | 1209 | |
| heute 06:46 | 1026 | |
| vor 40 Minuten | 821 | |
| 20.04.24, 12:11 | 608 | |
| vor 1 Stunde | 564 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.045,15 | +0,64 | 243 | |||
| 2. | 2. | 1,2000 | -13,04 | 98 | |||
| 3. | 3. | 0,1890 | 0,00 | 97 | |||
| 4. | 5. | 9,3050 | +0,65 | 86 | |||
| 5. | 4. | 160,88 | +1,39 | 78 | |||
| 6. | 6. | 7,0800 | +1,17 | 42 | |||
| 7. | 11. | 6,7680 | +0,71 | 37 | |||
| 8. | 12. | 2.346,92 | +0,64 | 33 |
Feedback
Hi Leutz, hört sich alles toll an allerdings ist der Penner in .fse nicht bereit die Shares zu einem fairen Kurs abzugeben.
250% Aufschlag auf den US Schlußkurs !
Das macht eine Mkap. von akt. ca. 150Mio $.
AGEN anschauen wer hier zocken will.
Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID, Presented at ASCO Plenary Session
First lymphoma vaccine to demonstrate disease-free survival benefit
Compassionate-use program to soon launch in Europe
On Sunday May 31, 2009, 10:30 am EDT
Buzz up! Print Related:Accentia Biopharmaceuticals, Inc., Biovest International Inc.
TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (Other OTC: BVTI - News), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ - News) today announced that an eight year pivotal, randomized, multi-center, double-blind, controlled Phase III clinical study has shown that BiovaxID® (personalized therapeutic anti-cancer vaccine) significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma. The study, which is being featured at today’s American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine – an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first ever vaccine targeting lymphoma to demonstrate such a disease-free survival benefit.
Related Quotes
Symbol Price Change
ABPIQ.PK 0.57 0.00
BVTI.PK 0.49 0.00
{"s" : "abpiq.pk,bvti.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} BiovaxID is individually manufactured from a tissue biopsy obtained from a patient’s own tumor, and selectively targets only the cancerous B-cells, while sparing healthy cells. BiovaxID is highly specific in its anti-lymphoma attack because the vaccine “trains” the body’s own immune system to recognize as foreign the unique protein (idiotype) expressed only on the cancerous B-cells, thus stimulating and recruiting the patient’s own immune system to destroy the cancer cells and potentially prevent recurrence. In contrast, other existing chemotherapeutic and monoclonal antibody therapies destroy most of the healthy B-cells in addition to the cancerous cells, and may result in serious adverse side-effects. Because the BiovaxID vaccine is comprised of the patient’s own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
The final vaccine is administered as a subcutaneous injection along with granulocyte-macrophage colony-stimulating factor (GM-CSF) and keyhole limpet hemocyanin (KLH), which together enhances the potency of the immune response induced by BiovaxID. A previous Phase II study demonstrated that patients receiving the BiovaxID vaccine developed a highly-specific immune response against tumor cells, with 95 percent of patients showing significant T-cell activity against their lymphoma and 75 percent of patients showing a humoral immune response. Furthermore, with a median follow-up of 9.2 years, 45 percent of patients remained in continuous first complete remission with a median disease-free survival of 8 years.
“With this vaccine, we’ve now moved into an era where we can safely use a patient’s immune system to effectively fight follicular lymphoma and enhance the response to conventional chemotherapy,” said Stephen J. Schuster, M.D., Associate Professor at the University of Pennsylvania School of Medicine and the study’s lead author. “Because this vaccine uniquely recruits the patient’s immune system to seek and destroy only tumor B-cells, this approach may be applicable to the treatment of other B-cell lymphomas.”
The completed Phase III study achieved its primary endpoint of prolonging disease-free survival in patients who were vaccinated with at least one injection of BiovaxID as compared to patients who received control. In the study, 177 patients with follicular lymphoma who had achieved a complete response to PACE (prednisone, doxorubicin, cyclophosphamide and etoposide) chemotherapy were randomized to the BiovaxID vaccine (Id-KLH/GM-CSF) or to the control study arm (KLH/GM-CSF). As prospectively identified, investigators analyzed the cohort of 117 randomized patients who, as required by the study protocol, maintained a complete response to chemotherapy for at least six months and who received active (N=76) or control (N=41) vaccine. After a median follow-up of 4.71 years (56.6 months, range: 12.6 - 89.3 months), the median disease-free survival in the BiovaxID arm was 44.2 months compared with 30.6 months in the control arm, which is a clinically and statistically significant difference (p=0.045).
BiovaxID demonstrated a favorable safety profile and was very well-tolerated by patients. Further studies are planned to examine the role of BiovaxID in patients with other B-cell lymphomas such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. In addition, new lymphoma studies will evaluate the addition of BiovaxID booster maintenance therapy, which is expected to even further improve survival benefits by maximizing the chance of continuously maintaining complete remissions.
“BiovaxID is a 100% personalized medicine with each vaccine unique to each patient,” stated Biovest’s Chairman and CEO, Francis E. O’Donnell, Jr., M.D. “Despite the failures of other lymphoma vaccines and the skepticism in general towards patient-specific cancer immunotherapies, our unprecedented results presented today are a tribute to the more than 37 years of dedicated vision and labor by researchers dating back to the first mouse studies using this approach in the early 1970s. We congratulate and thank all that have been involved at every level in developing this ultimate targeted therapy, with special recognition to the National Cancer Institute, who with our Biovest team, advanced BiovaxID in human clinical trials. And we also offer our profound thanks to the investigators, and more importantly to the patients that participated in our Phase II and Phase III clinical trials, as their courage in fighting this insidious disease is inspiring. It is only because of their contribution, and with the support of their family and friends, that such potential breakthrough new therapies can be evaluated and ultimately made available to all patients in need.”
In addressing regulatory and commercial plans for BiovaxID, Biovest’s President and General Counsel, Samuel Duffey, commented, “We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways. In addition, we plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed.”
Biovest also reported that the Company expects to publish the final comprehensive results in a peer-reviewed scientific publication later this year.
About BiovaxID®
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell’s surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient’s tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient’s T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. Unlike other failed cancer vaccine therapies that attempted to target lymphoma, BiovaxID is the only hybridoma (patient’s lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as “training” the immune system to maintain continuous response if cancerous cells were to return.
About Biovest International, Inc.
Biovest International, Inc. (Other OTC: BVTI - News) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned (75%) subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ - News) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
For further information, please visit: http://www.biovest.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Contact:
Biovest International, Inc.
Douglas Calder, Director of Investor Relations & Public Relations
813-864-2554, ext. 258
Email: dwcalder@biovest.com
250% Aufschlag auf den US Schlußkurs !
Das macht eine Mkap. von akt. ca. 150Mio $.
AGEN anschauen wer hier zocken will.
Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID, Presented at ASCO Plenary Session
First lymphoma vaccine to demonstrate disease-free survival benefit
Compassionate-use program to soon launch in Europe
On Sunday May 31, 2009, 10:30 am EDT
Buzz up! Print Related:Accentia Biopharmaceuticals, Inc., Biovest International Inc.
TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (Other OTC: BVTI - News), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ - News) today announced that an eight year pivotal, randomized, multi-center, double-blind, controlled Phase III clinical study has shown that BiovaxID® (personalized therapeutic anti-cancer vaccine) significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma. The study, which is being featured at today’s American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine – an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first ever vaccine targeting lymphoma to demonstrate such a disease-free survival benefit.
Related Quotes
Symbol Price Change
ABPIQ.PK 0.57 0.00
BVTI.PK 0.49 0.00
{"s" : "abpiq.pk,bvti.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} BiovaxID is individually manufactured from a tissue biopsy obtained from a patient’s own tumor, and selectively targets only the cancerous B-cells, while sparing healthy cells. BiovaxID is highly specific in its anti-lymphoma attack because the vaccine “trains” the body’s own immune system to recognize as foreign the unique protein (idiotype) expressed only on the cancerous B-cells, thus stimulating and recruiting the patient’s own immune system to destroy the cancer cells and potentially prevent recurrence. In contrast, other existing chemotherapeutic and monoclonal antibody therapies destroy most of the healthy B-cells in addition to the cancerous cells, and may result in serious adverse side-effects. Because the BiovaxID vaccine is comprised of the patient’s own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
The final vaccine is administered as a subcutaneous injection along with granulocyte-macrophage colony-stimulating factor (GM-CSF) and keyhole limpet hemocyanin (KLH), which together enhances the potency of the immune response induced by BiovaxID. A previous Phase II study demonstrated that patients receiving the BiovaxID vaccine developed a highly-specific immune response against tumor cells, with 95 percent of patients showing significant T-cell activity against their lymphoma and 75 percent of patients showing a humoral immune response. Furthermore, with a median follow-up of 9.2 years, 45 percent of patients remained in continuous first complete remission with a median disease-free survival of 8 years.
“With this vaccine, we’ve now moved into an era where we can safely use a patient’s immune system to effectively fight follicular lymphoma and enhance the response to conventional chemotherapy,” said Stephen J. Schuster, M.D., Associate Professor at the University of Pennsylvania School of Medicine and the study’s lead author. “Because this vaccine uniquely recruits the patient’s immune system to seek and destroy only tumor B-cells, this approach may be applicable to the treatment of other B-cell lymphomas.”
The completed Phase III study achieved its primary endpoint of prolonging disease-free survival in patients who were vaccinated with at least one injection of BiovaxID as compared to patients who received control. In the study, 177 patients with follicular lymphoma who had achieved a complete response to PACE (prednisone, doxorubicin, cyclophosphamide and etoposide) chemotherapy were randomized to the BiovaxID vaccine (Id-KLH/GM-CSF) or to the control study arm (KLH/GM-CSF). As prospectively identified, investigators analyzed the cohort of 117 randomized patients who, as required by the study protocol, maintained a complete response to chemotherapy for at least six months and who received active (N=76) or control (N=41) vaccine. After a median follow-up of 4.71 years (56.6 months, range: 12.6 - 89.3 months), the median disease-free survival in the BiovaxID arm was 44.2 months compared with 30.6 months in the control arm, which is a clinically and statistically significant difference (p=0.045).
BiovaxID demonstrated a favorable safety profile and was very well-tolerated by patients. Further studies are planned to examine the role of BiovaxID in patients with other B-cell lymphomas such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. In addition, new lymphoma studies will evaluate the addition of BiovaxID booster maintenance therapy, which is expected to even further improve survival benefits by maximizing the chance of continuously maintaining complete remissions.
“BiovaxID is a 100% personalized medicine with each vaccine unique to each patient,” stated Biovest’s Chairman and CEO, Francis E. O’Donnell, Jr., M.D. “Despite the failures of other lymphoma vaccines and the skepticism in general towards patient-specific cancer immunotherapies, our unprecedented results presented today are a tribute to the more than 37 years of dedicated vision and labor by researchers dating back to the first mouse studies using this approach in the early 1970s. We congratulate and thank all that have been involved at every level in developing this ultimate targeted therapy, with special recognition to the National Cancer Institute, who with our Biovest team, advanced BiovaxID in human clinical trials. And we also offer our profound thanks to the investigators, and more importantly to the patients that participated in our Phase II and Phase III clinical trials, as their courage in fighting this insidious disease is inspiring. It is only because of their contribution, and with the support of their family and friends, that such potential breakthrough new therapies can be evaluated and ultimately made available to all patients in need.”
In addressing regulatory and commercial plans for BiovaxID, Biovest’s President and General Counsel, Samuel Duffey, commented, “We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways. In addition, we plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed.”
Biovest also reported that the Company expects to publish the final comprehensive results in a peer-reviewed scientific publication later this year.
About BiovaxID®
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell’s surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient’s tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient’s T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. Unlike other failed cancer vaccine therapies that attempted to target lymphoma, BiovaxID is the only hybridoma (patient’s lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as “training” the immune system to maintain continuous response if cancerous cells were to return.
About Biovest International, Inc.
Biovest International, Inc. (Other OTC: BVTI - News) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned (75%) subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ - News) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
For further information, please visit: http://www.biovest.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Contact:
Biovest International, Inc.
Douglas Calder, Director of Investor Relations & Public Relations
813-864-2554, ext. 258
Email: dwcalder@biovest.com
Antwort auf Beitrag Nr.: 37.293.840 von nomis am 01.06.09 10:55:35da kommen noch einige bios demnächst !!!!!!
Antwort auf Beitrag Nr.: 37.294.307 von Fortunato69 am 01.06.09 11:57:09Wartet ab es kommen noch andere wie mein Vorredner schon sagte.
Schaut auf GNTA,HEB
Schon gute Daten gemeldet hat auch KERX.
Schaut auf GNTA,HEB
Schon gute Daten gemeldet hat auch KERX.
Antwort auf Beitrag Nr.: 37.294.880 von Woddy01 am 01.06.09 13:20:33Biovest Int. hat heute um 290% zugelegt...
Non-Hodgkin’s lymphoma.
Und auch hier eingekauft, Biotechs sind iMo sehr verheißungsvoll.
Und auch hier eingekauft, Biotechs sind iMo sehr verheißungsvoll.
Trading Spotlight
Ist ja im Moment frustrierend. Aber bei Biotechs gilt auch Prinzip Hoffnung. Wer weiss...
Na, da bewegt sich doch was Wird viel zu wenig beachtet
Wird viel zu wenig beachtet
Ach ja, vergaß den Grund des 30 %-Sprungs zu notieren, wird wohl spannend
http://finance.yahoo.com/news/Personalized-AntiCancer-bw-953…
http://finance.yahoo.com/news/Personalized-AntiCancer-bw-953…
+ 20 US-Cent/57 %
Da tut sich was, weiss nicht warum, egal, das Warten hat sich möglicherweise gelohnt.
Da tut sich was, weiss nicht warum, egal, das Warten hat sich möglicherweise gelohnt.
Da tut sich was, weiss noch nicht genau was, aber die scheinen, so weit ichs begreife, ihre Finanzen unter Kontrolle gebracht zu haben.
0,73 US-Dollar
Toll, in zwei Tagen nen Verdoppler hingelegt. Und keiner weiss so recht warum
Antwort auf Beitrag Nr.: 38.035.168 von glaubehoffnung am 22.09.09 22:17:18nun eigentlich gibt es auch nichts neues, nur altes wurde frisch aufbereitet gucksdu da
As individuals in our respective societies, we all abide by a certain moral standing. However, regardless of your lifestyle, you will adhere to the notion that there is no greater feeling in the world than knowing you are helping fund a company which could potentially save millions of lives, while at the same time fulfilling your needs through growing your pockets as well. So without further ado, let’s all welcome Biovest International, Inc. (OTC:BVTI) as StocksHaven Investment’s newest company profile. Recently the company has stricken interest from the investment community through its product, BiovaxID, which has seen very positive Phase III results presented at Asco Plenary Session. BiovaxID is truly revolutionary, the cancer vaccine evokes the power of each patient’s immune system and primes it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. Before beginning the analysis, lets also keep in mind that with the phase III were presented nearly four months ago on 05/31/09, meaning an NDA announcement could come at anytime. Biovest’s President, Samuel Duffey states, ““We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways.”
As individuals in our respective societies, we all abide by a certain moral standing. However, regardless of your lifestyle, you will adhere to the notion that there is no greater feeling in the world than knowing you are helping fund a company which could potentially save millions of lives, while at the same time fulfilling your needs through growing your pockets as well. So without further ado, let’s all welcome Biovest International, Inc. (OTC:BVTI) as StocksHaven Investment’s newest company profile. Recently the company has stricken interest from the investment community through its product, BiovaxID, which has seen very positive Phase III results presented at Asco Plenary Session. BiovaxID is truly revolutionary, the cancer vaccine evokes the power of each patient’s immune system and primes it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. Before beginning the analysis, lets also keep in mind that with the phase III were presented nearly four months ago on 05/31/09, meaning an NDA announcement could come at anytime. Biovest’s President, Samuel Duffey states, ““We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways.”
Antwort auf Beitrag Nr.: 38.035.602 von dottore am 22.09.09 23:27:15http://www.stockshaven.com/biovest-inches-closer-to-cancer-v…
hier noch die Quelle
hier noch die Quelle
Seufz, der gestrige Gewinn fast wieder weg. Also gehts Warten weiter
So wie ichs im Ami-Yahoo verstanden hab, soll am 10.12. Gerichtstermin(ursprünglich + angeblich für 4.12. geplant)/Vorlage wg Restrukturierung oder was auch immer sein.
Ist ja n lustiger Wert: Pleite, aber angeblich ne erfolgversprechende Technologie in Entwicklung oder wo oder was auch immer.
Alles unter Vorbehalt, Genaues scheint im Internet niemand zu wissen, lest euch ggf ein
Ist ja n lustiger Wert: Pleite, aber angeblich ne erfolgversprechende Technologie in Entwicklung oder wo oder was auch immer.
Alles unter Vorbehalt, Genaues scheint im Internet niemand zu wissen, lest euch ggf ein
Niemand mehr da?
Ich hab zwar keinen richtigen Plan von Biovest, niemand scheint nirgends den Gang der Dinge zu kennen, aber vllt isses für ne Überraschung gut.
Vielleicht wirds ja mein Vanda, oder Cannae...
Vielleicht wirds ja mein Vanda, oder Cannae...
Sie träumen von einer neuen Dendreon.
Artikel zu Accentia, 75%-Eigentümer von Biovest.
Interessant
http://biopharmaceuticalnews.blogspot.com/2009/12/accentia-b…
Artikel zu Accentia, 75%-Eigentümer von Biovest.
Interessant
http://biopharmaceuticalnews.blogspot.com/2009/12/accentia-b…
Für die Biovest-75%-Teilhaberin Accentia wird jetzt im Ami-Yahoo der 22.12. als nächster Termin betr. Restrukturierung usw gehandelt, so hab ichs wenigstens verstanden.
Hat vllt/wahrscheinlich auch Auswirkungen auf Biovest!??
Hat vllt/wahrscheinlich auch Auswirkungen auf Biovest!??
Der Pleitegeier beginnt zu fliegen, es wird spannend
http://finance.yahoo.com/news/FDA-Grants-Orphan-Drug-Status-…
http://finance.yahoo.com/news/FDA-Grants-Orphan-Drug-Status-…
Antwort auf Beitrag Nr.: 38.687.402 von glaubehoffnung am 07.01.10 20:10:06Orphan-Status, noch ne Meldung
http://www.earthtimes.org/articles/show/fda-grants-orphan-dr…
Vielleicht wirds doch noch meine kleine Ersatz-Vanda
http://www.earthtimes.org/articles/show/fda-grants-orphan-dr…
Vielleicht wirds doch noch meine kleine Ersatz-Vanda
Im Moment schon plus 70 %
100%, erst ca. 71 Mio $ wert
Antwort auf Beitrag Nr.: 38.687.578 von glaubehoffnung am 07.01.10 20:23:33glückwunsch glaube, haste ja sauber durchgehalten, das teil fliegt förmlich.
!
Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users!
Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users!
Dieser Beitrag wurde moderiert. Grund: Korrespondierendes Posting wurde entfernt!
Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users
Na, heut eher verhalten, Abwarten scheint wohl angesagt
Antwort auf Beitrag Nr.: 38.696.478 von glaubehoffnung am 08.01.10 18:22:45KORREKTUR: Highnoon bis Mitte 2010
http://stlouis.bizjournals.com/stlouis/stories/2010/01/04/da…
http://stlouis.bizjournals.com/stlouis/stories/2010/01/04/da…
Projektion, interessant
http://sec.gov/Archives/edgar/data/704384/000119312506152662…" target="_blank" rel="nofollow ugc noopener">
http://sec.gov/Archives/edgar/data/704384/000119312506152662…
http://sec.gov/Archives/edgar/data/704384/000119312506152662…" target="_blank" rel="nofollow ugc noopener">
http://sec.gov/Archives/edgar/data/704384/000119312506152662…
Betr. Reorganisation, aus Ami-Chat, die Gefahr der Aktien-Löschung scheint nicht mehr gegeben. Ich lass mich überraschen, bis Sommer sollte vllt alles klarer sein
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Interessanter Eintrag zu den Chancen von Biovest
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Da scheint wohl was in Bewegung gekommen zu sein
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
... und keiner schaut hin
Uff, Biovest in $ iMo 25 %, Accentia (Mehrheitsmutter) 50 % Plus.
Es wird spannend.
Es wird spannend.
Antwort auf Beitrag Nr.: 39.052.366 von glaubehoffnung am 03.03.10 18:12:25Du bist nicht allein!
Was, schon 2 !??
Zittern wir uns weiter.
Glaub, also unter größtem Vorbehalt, dass um den 10.3. Stichtag für die Insolvenz-Folgeregelung(vielleicht auch nur für die Mehrheitsmutter Accentia!??) sein könnte, ggf auch wieder verlängerbar, angeblich um den 10.5. solls um die Zulassung gehn.
Alles nur Erinnerung und mit Vorsicht zu geniessen, überhaupt steht immer noch die Gefahr im Raum, dass die Aktien "gelöscht" werden. Lest euch selbst ein, alles sehr gefährlich.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Ein heisser Ritt
Zittern wir uns weiter.
Glaub, also unter größtem Vorbehalt, dass um den 10.3. Stichtag für die Insolvenz-Folgeregelung(vielleicht auch nur für die Mehrheitsmutter Accentia!??) sein könnte, ggf auch wieder verlängerbar, angeblich um den 10.5. solls um die Zulassung gehn.
Alles nur Erinnerung und mit Vorsicht zu geniessen, überhaupt steht immer noch die Gefahr im Raum, dass die Aktien "gelöscht" werden. Lest euch selbst ein, alles sehr gefährlich.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Ein heisser Ritt
Macht auch heute Spass
Und auch heute geht wieder die Post ab, toller Chart
http://finance.yahoo.com/echarts?s=BVTI.PK#chart1:symbol=bvt…
http://finance.yahoo.com/echarts?s=BVTI.PK#chart1:symbol=bvt…
Präsentationen / Termine in April, Mai, Juni
http://finance.yahoo.com/news/Biovest-Announces-Upcoming-bw-…
http://finance.yahoo.com/news/Biovest-Announces-Upcoming-bw-…
1,50 $, + 20 %, baut sich wohl wieder Hoffnung für den nächsten Termin auf!?
Und 1,78 $, mit dem Möbel lässt sich gut handeln
Der 2. Zulassungs-Lauf einer Vakzine nach Dendreon, lasset uns hoffen...
Antwort auf Beitrag Nr.: 39.534.144 von glaubehoffnung am 17.05.10 18:54:56Könnte für gute Laune sorgen!?
http://singularityhub.com/2010/07/17/new-cancer-vaccine-kill…
http://singularityhub.com/2010/07/17/new-cancer-vaccine-kill…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 243 | ||
| 98 | ||
| 97 | ||
| 86 | ||
| 78 | ||
| 42 | ||
| 37 | ||
| 33 | ||
| 33 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 29 | ||
| 26 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 23 | ||
| 22 | ||
| 22 | ||
| 21 | ||
| 20 |
